Objective: To assess the cardiovascular disease (CVD) and venous thromboembolism (VTE) risks among patients with newly diagnosed antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). Patients and Methods: A population-based incident AAV cohort of 58 patients diagnosed between 1996 and 2015 in Olmsted County, MN, was identified by medical record review. For each patient, 3 age-and sex-matched non-AAV comparators were randomly selected from the same population and assigned an index date corresponding to the AAV incidence date. Medical records of cases and comparators were reviewed for CVD events, which included cardiac events (coronary artery disease, heart failure, and atrial fibrillation), cerebrovascular accidents (CVA), peripheral vascular disease (PVD), and VTE, which included deep vein thrombosis (DVT) and pulmonary embolism (PE). Results: Baseline total cholesterol, high-density lipoprotein, and current smoking rate were lower in AAV than in comparators (P¼.03, P¼.01, and P¼.04, respectively), whereas other CVD risk factors and Framingham risk score were not significantly different between the 2 groups. The CVD events developed in 13 patients and 17 comparators, corresponding to a more than 3-fold increased risk (hazard ratio [HR], 3.15; 95% CI, 1.51-6.57). By subtypes, risks were increased for cardiac events (HR, 2.96; 95% CI, 1.42-6.15) and CVA (HR, 8.16; 95% CI,), but not for PVD. The HR for VTE was 3.26 (95% CI, 0.84-12.60), significantly increased for DVT (HR, 6.25; 95% CI, 1.16-33.60), but not for PE (HR, 1.33; 95% CI,. Conclusion: Despite a similar prevalence of CVD risk factors at baseline, the risk of CVD is more than 3-fold higher and for CVA 8-fold higher in patients with incident AAV than in matched comparator subjects.
A ntineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a heterogeneous group of systemic diseases characterized by inflammation of smalland medium-sized vessels, [1] [2] [3] variably associated with ANCAs directed against proteinase 3 (PR3) or myeloperoxidase (MPO). [3] [4] [5] Among AAV, granulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis) and microscopic polyangiitis (MPA) are the 2 most common subtypes, and with eosinophilic granulomatosis with polyangiitis (EGPA, formerly ChurgStrauss syndrome) account for an estimated combined prevalence of 42.1 per 100,000 adult population in the United States. 6 Modern treatments have greatly improved survival in AAV, [7] [8] [9] [10] but many patients suffer cardiovascular and thrombotic complications during long-term follow-up. 11, 12 Overall, patients with AAV appear at a greater risk for cardiovascular disease (CVD) 13 and have an increased CVD-related mortality due to accelerated atherosclerosis. 14 Significantly increased risks of myocardial infarction (MI) and ischemic stroke have been reported in GPA. 12, 14, 15 However, other studies reported a nonestatistically significant trend toward an increased risk of ischemic stroke, 12, 13, 15 or an identical risk of stroke and even lower risk of acute coronary syndrome compared with matched controls. 13 Different study designs, different comparator populations, and case ascertainment strategies may explain the heterogeneity of findings among these different studies and hamper direct comparisons among them. Only a few population-based investigations of CVD risk have been performed in all forms of AAV including MPA and EGPA.
An increase in the risk for venous thromboembolism (VTE) has been observed in AAV, with a close temporal relationship with active disease, [16] [17] [18] [19] [20] although the risk for developing VTE also remains increased during inactive AAV. 21 Population-based studies specifically addressing the risks for heart failure (HF), atrial fibrillation (AF), and peripheral vascular disease (PVD) in patients with AAV have not yet been conducted, although cardiac involvement has been reported to be twice as common in patients with GPA, and 3 times as common in EGPA than in comparators from the general population. 22 The current study aimed to better characterize the risk for CVD and thrombotic events among newly diagnosed patients with GPA, MPA, and EGPA in the Olmsted County, Minnesota, adult population, from 1996 to 2015. The incidence of CVD and VTE in patients with AAV was compared with that in sex-and age-matched comparator subjects without AAV, randomly selected from the same population.
PATIENTS AND METHODS

Data Sources
All patients with AAV and comparators were residents of Olmsted County, Minnesota, where the Rochester Epidemiology Project (REP) systematically collects clinical records of all residents seeking medical care. Because of the availability of this comprehensive medical data, the population of Olmsted County is particularly suitable for the investigation of AAV epidemiology.
This record linkage system allows direct access to the medical records of both inpatients and outpatients, from all health care providers in Olmsted County, including Olmsted Medical Center and Mayo Clinic and their affiliated hospitals, local nursing homes, and the few private general practitioners.
The utility of this data system in population-based studies has previously been described. [23] [24] [25] The REP facilitates complete ascertainment of the outcomes of interest (ie, any CVD and VTE) for AAV cases and comparators among Olmsted County residents.
Case Ascertainment
Incident cases of AAV from January 1, 1996, to December 31, 2015 , in this geographically defined region of the United States were previously identified by medical record review. 6 The AAV cases were included if they fulfilled the criteria of at least 1 of the following classification schemes: American College of Rheumatology (ACR) classification criteria or the modified ACR criteria for GPA, 26, 27 ACR criteria for EGPA, 28 Chapel Hill Consensus Conference definition, 29 or European Medical Agency algorithm. 30 Organ involvement and disease activity at disease incidence were described using items and domains of the Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG). 31 Renal insufficiency was defined as an estimated glomerular filtration rate of less than 60 mL/ min/1.73 m 2 . For each patient with incident AAV, 3 age (AE3 years) and sex-matched comparators without AAV were randomly selected from the Olmsted County population, and assigned an index date corresponding to the incidence date of AAV.
Cardiovascular and Thrombotic Diseases Ascertainment
Data on CVD risk factors at baseline, which included hypertension, diabetes mellitus, dyslipidemia, body mass index [calculated as the weight in kilograms divided by the height in meters squared], and smoking status, were collected. Medical records of all cases and comparators were reviewed for the events of interest, that is, CVD and VTE. The former included coronary artery disease (CAD), AF, HF, cerebrovascular accident (CVA), and PVD. The VTE events included deep vein thrombosis (DVT) and pulmonary embolism (PE).
Coronary artery disease included both fatal and nonfatal MI. Classification of CAD was based on physician diagnosis as entered in the medical record, and was supported by coronary angiography, when performed. Coronary revascularization procedures (percutaneous transluminal coronary angioplasty and coronary artery bypass grafting) were also defined as CAD. Classification of HF was based on the Framingham criteria for HF. 32 Atrial fibrillation was classified on the basis of electrocardiography reports. Cerebrovascular accident was defined as ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, transient ischemic attack, amaurosis fugax, or death from CVA. Cerebrovascular accident was classified by physician diagnosis, and was verified by cerebrospinal fluid analysis or imaging. Transient ischemic attack was defined by physician diagnosis and negative brain imaging studies. Peripheral vascular disease included peripheral arterial disease, abdominal aortic aneurysm, renal artery stenosis, or arterial thromboembolism. Peripheral arterial disease was defined by a resting ankle-brachial systolic pressure index of 0.9 or less. 33 Classification of abdominal aortic aneurysm required imaging showing the diameter of the abdominal aorta more than 1.5 times normal diameter. 34 Renal artery stenosis was verified by ultrasound/renal scintigraphy/ angiography, and arterial thromboembolism was based on clinical diagnosis supported by angiography. Deep vein thromboses were verified by ultrasound or phlebography/venography and PE by computed tomography angiography, arteriography, or scintigraphy.
The 10-year general Framingham risk score for CVD was calculated. When lipid values were not available, the office-based 10-year Framingham risk score, which does not include laboratory values, was used. 35 All patients with active disease were treated with an induction therapy (glucocorticoid plus methotrexate, mycophenolate mofetil, cyclophosphamide, or rituximab) followed by a maintenance treatment of variable duration (glucocorticoids, rituximab, methotrexate, azathioprine, mycophenolate mofetil, trimethoprim/sulfamethoxazole, alone or in combination). Follow-up was continued until death, migration, or January 1, 2017. The study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center.
Statistical Analyses
Descriptive statistics (percentages, mean, etc) were used to summarize the characteristics of each cohort. c 2 and rank sum tests were used for comparisons between the cohorts.
Fisher exact test was used to examine whether there were increases in the prevalence of any CVD and VTE overall and by subtype before the development of AAV between the cohorts. The CVD and VTE cumulative incidence overall and by subtype adjusted for the competing risk of death was estimated. 36 These methods are similar to the Kaplan-Meier method, with censoring of patients who are still alive at last follow-up. However, patients who died before the occurrence of CVD or VTE events are appropriately accounted for to avoid overestimation of the rate of occurrence of these events, which is possible if such subjects are simply censored at death. For each type of CVD and VTE, cases in which first occurrence was before the diagnosis of AAV, or before the index date for subjects in the non-AAV comparison cohort, were excluded from the analysis of cumulative incidence.
For the estimation of the overall CVD and VTE cumulative incidence, the date of occurrence was the earliest date of occurrence of any of the individual CVD or VTE events. Cox proportional hazard ratios (HRs) were used to compare the rate of development of CVD and VTE, individually and in combination, between patients with AAV and the non-AAV comparison cohort. These models were also used to examine the association between AAV-related features and development of CVD. First, relapse was modeled as a time-dependent covariate. Person-year methods were used to examine the rates of CVD/VTE events according to time since AAV incidence/index date. Rate ratios comparing the AAV and non-AAV cohorts were computed. Ninety-five percent CIs were obtained by assuming that the rates followed the Poisson distribution. A P value of less than .05 was considered statistically significant for all analyses. Analyses were performed using SAS version 9.4 (SAS Institute) and R version 3.2.3 (R Foundation for Statistical Computing).
RESULTS
Baseline Characteristics of AAV Cases and Comparators
Baseline demographic and clinical characteristics of AAV cases and comparators are described in Table 1 . Median (interquartile range) length of follow-up was 6.5 (2.8-11.3) years for AAV and 6.7 (4.1-8.9) years for comparators. Among the 58 incident AAV cases identified, 48% were women and 98% white, with a mean AE SD age of 61.1AE16.5 years. Of the 174 non-AAV comparators, 48% were women and 95% were white, with a mean AE SD age of 61.2AE16.3 years. The AAV cases included 23 (40%) GPA, 28 (48%) MPA, and 7 (12%) EGPA. ANCA antibody testing was performed in 56 (97%) patients at diagnosis, with positive result for MPO-AAV in 34 (61%) patients, for PR3-AAV in 17 (30%) patients, and a negative ANCA result in 5 (9%) patients.
Baseline total cholesterol (median, 179 mg/dL for AAV; 191 mg/dL for comparators; P¼.03), high-density lipoprotein (median, 47 vs 53 mg/ dL; P¼.01), and current smoking (5% vs 19%; P¼.04) were lower in AAV than in comparators. The other CVD risk factors were not significantly different between the 2 groups.
At disease incidence, patients with MPA were older than patients with GPA or EGPA (mean AE SD, 67.6AE16.2 vs 56.1AE15.1 vs 51.5AE13.4 years, respectively) (Supplemental Table, available online at http://www. mayoclinicproceedings.org). After adjustment for age and sex, hypertension was found to be more frequent in patients with MPA than in patients with GPA at AAV diagnosis (79% vs 43%; P¼.04), as well as the use of antihypertensive medication (78% vs 36%; P¼.01) (Supplemental Table) . None of the patients had clinical or serologic evidence of antiphospholipid antibody syndrome or other thrombophilic disorders.
Association Between AAV and Incident CVD and VTE Overall CVD and VTE prevalence before the date of diagnosis/index date was not significantly different between patients with AAV and the non-AAV comparison cohort (27% and 28%, respectively; P¼.93). Table 2 presents CVD and VTE cumulative incidence after diagnosis/index date for cases and comparators.
The CVD events developed in 13 patients with AAV and 17 comparators. The risk of incident CVD adjusted for age, sex, and calendar year was significantly higher among patients with AAV (HR, 3.15; 95% CI, 1.51-6.57) ( Figure 1A ). After adjusting for smoking status, presence of diabetes mellitus, presence of hypertension, use of antihypertensives, presence of dyslipidemia, and use of lipid-lowering medications, the risk of CVD was even higher (HR, 4.62; 95% CI, 1.87-11.42; P<.001).
By subtypes, age-and sex-adjusted risks were increased for cardiac events (CAD, HF, Table 2) .
The factors associated with CVD events in the AAV cohort were age (HR per 10-year increase, 2.03; 95% CI, 1.26-3.25), obesity (body mass index, !30 kg/m 2 ; age-adjusted HR, 4.32; 95% CI, 1.30-14.31), dyslipidemia (age-adjusted HR, 7.07; 95% CI, 1.88-26.54), and diabetes mellitus type II (ageadjusted HR, 7.42; 95% CI, 1.59-34.64). The other demographic (sex, calendar year of AAV diagnosis), cardiovascular (previous or current smoking habit, hypertension), and AAV-related features tested (BVAS-WG at diagnosis, renal insufficiency, C-reactive protein, clinical diagnosis of GPA vs MPA, ANCA specificity, relapse) were not associated with CVD risk.
The incidence rate of overall CVD events during follow-up was calculated according to time after AAV incidence/index date (Table 3 ; Figure 2 ). In the AAV cohort, this rate was greatest in the first 2 years after diagnosis (6.89 per 100 person-years; 95% CI, 2.24-16.06), and gradually declined in subsequent years. In contrast, this rate was stable over time during the first 10 years of follow-up in the comparator cohort at about 2 events per 100 person-years (95% CI, 1.2-3.2). Consequently, when compared with non-AAV comparators, the rate ratio was highest for the first 2 years after diagnosis (rate ratio, 3.43; 95% CI, 0.99-11.90) and decreased thereafter.
DISCUSSION
This population-based study demonstrates that patients with AAV, despite similar baseline CV risk factors and history of prior CVD, are at more than 3 times higher risk for CVD overall compared with the general population, a risk that is more than 4-fold after baseline CVD risk factor adjustment, and at 6 times higher risk for DVT. Moreover, this is the first study to demonstrate a substantially increased incidence of CVA in patients with AAV. This CVD risk is especially increased during the first 2 years after diagnosis. The Patients with a specific previous event were excluded from that individual category. Data are presented as n/n, unless otherwise stated. main baseline factors associated with this increased risk are older age and some traditional CV risk factors (obesity, diabetes mellitus, and dyslipidemia), which need to be aggressively treated in these high-risk patients.
In contrast to most of the previous studies reporting an increased risk of MI in patients with AAV, 12, 13, 15, 37 the results of the current study found no increase in MI. The higher cumulative incidence of cardiac events overall was mainly driven by a higher incidence of HF. A large population-based study recently reported an approximately doubled risk of MI in patients with GPA. 12 As discussed by the authors, the accuracy of that study may have been limited by its design, which used an administrative registry to identify the patients and the outcomes of interest without further verification of individual medical records, with a potential overascertainment of cases and events.
Other authors have reported an increased risk of MI, especially during the first 5 years after the diagnosis. 15, 38 However, these were not population-based studies with matched comparators. One of them identified patients using hospital registries, 15 which could potentially decrease the incidence denominator by selecting only patients with more severe disease. Another study used data from patients included in clinical trials, 38 who are likely at a higher risk for CVD because they are older and have higher rates of renal impairment and higher disease activity scores than do patients in observational cohorts. 39 The incidence of CVA in the current study was markedly higher in patients with AAV compared with the general population. Indeed, the CVA risk was more than 8 times higher than that of comparator subjects, and was driven by ischemic strokes. One of the biggest singlecenter GPA cohorts reported neurological involvement in 33.6% of patients, but only 16 out of 324 patients had stroke. 40 To our knowledge, the only population-based study to assess the risk of ischemic stroke in AAV reported a moderately increased risk in patients with GPA compared with matched non-GPA comparator subjects (HR, 1.50), without reaching statistical significance. 12 A possible contributor to the higher stroke prevalence in the current study is that cardiovascular risk factors could be higher in the general population of the United States compared with that of Canada. The only directly comparable cardiovascular risk factor in the current and the population-based Canadian study was obesity, present in about 30% of cases and comparator subjects in the current study, compared with less than 1% in the Canadian study. 12 Notably, no patients in the current study had a clinical diagnosis of antiphospholipid syndrome, which is rarely reported to coexist with AAV and to be the cause of thromboembolic and CVA complications. 41 Ultimately, many factors could have contributed to the finding of increased CVA risk in the current study, highlighting the importance of CVA among all other CVD complications suffered by patients with AAV.
Premature atherosclerosis associated with inflammation is likely the key driver behind the increased risk for CVD events in patients with AAV, 42 related to increased local and systemic expression of several proinflammatory cytokines. 43 This hypothesis is particularly appealing because the prevalence of CVD risk factors in this cohort was similar between patients with AAV and matched comparators at baseline, but it was strongly associated with the subsequent risk of developing CVD risk in the AAV cohort. Interestingly, baseline AAV-related factors (such as C-reactive protein, BVAS-WG, ANCA specificity, or renal insufficiency due to vasculitis) did not per se increase this CVD risk. It is possible that inflammation due to vasculitis might trigger an acceleration of atherosclerosis in those predisposed individuals, with a higher CVD risk at diagnosis. At present, however, it is still not clear how much the systemic and vascular inflammatory process may contribute to the pathogenesis of CVD among patients with AAV.
Finally, in this study, the incidence of VTE in patients with AAV was more than 3 times higher than in comparator subjects, significantly increased for DVT (>6 times), but not for PE. This result is consistent with previous observations of an increased incidence of VTE in AAV, [18] [19] [20] suggesting that some disruption of venous endothelium in AAV might create a microenvironment promoting thrombosis.
Although it is well documented that a history of CVD events predicts the risk of subsequent CVD and CVA in the general population and in AAV as well, 13, 44, 45 unlike the current study, most of the previous AAV studies usually did not exclude patients with prior events from the risk analyses, thus potentially leading to overestimation of the risk of CVD in patients with AAV. The current study, instead, gives a clearer picture of CVD risk in patients with AAV. Its major strength is the population-based design and the utilization of the REP, a comprehensive record linkage system that allows capture of virtually all clinically recognized cases of AAV in Olmsted County, including those patients with mild/localized GPA that may be omitted from hospital-based databases. The diagnosis of AAV was verified by medical record review, minimizing the likelihood of overdiagnosis or physician-based diagnosis not fulfilling international classification criteria, a common concern in coding-based studies. The limitations of this study are those inherent to its retrospective nature. First, clinical information of the patients was not systematically obtained by the treating physicians following an established protocol. Consequently, some of the pertinent clinical data might not have been documented in the medical record, and the BVAS/WG scoring, for instance, could have been imprecise for that reason. Because this study is based on retrospective review of data recorded in the clinical record, ascertainment bias, classification error, survivor treatment selection, and other biases cannot be completely excluded. However, the results reflect a real-life setting and therefore should have relevance for routine patient care. Second, differences in CVD risk between MPA and GPA or between MPO-AAV and PR3-AAV described in other cohorts were not detected in the current study. The relatively small base population may have lacked power to detect differences between these subgroups; however, even with a larger cohort, these differences among clinical subtypes of AAV and ANCA serology subgroups would still have been smaller than the effect of traditional CVD risk factors. Third, the results of this study may or may not reflect AAV in communities with a different racial/ethnic composition, such as those with a high prevalence of blacks or Asians. However, the findings can be carefully generalized to adult subjects with similar age, sex, race/ethnicity, and living in the Midwest or Northern United States, and provide a useful point of reference for the estimation of these risk factors and disease outcomes.
CONCLUSION
This long-term follow-up study demonstrates that patients with AAV are at increased risk for any CVD and DVT, with a risk more than 3 times higher for CVD overall, and more than 8 times higher for CVA, compared with matched comparator subjects from the same population. In contrast to some previous reports, the risk of CAD in patients with AAV is not significantly higher than that in the general population when patients with prior CVD events are excluded from the analysis. The risk for CVD in patients with AAV is increased, particularly in the first 2 years following disease occurrence, gradually declining thereafter. For the clinician and patient, active vigilance for any CVD and VTE, and an aggressive treatment of CVD risk factors is recommended, especially in the first years after diagnosis of AAV.
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